Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cti Biopharm Corp (CTIC)

Cti Biopharm Corp (CTIC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 77,403
  • Shares Outstanding, K 73,717
  • Annual Sales, $ 3,350 K
  • Annual Income, $ -40,020 K
  • 60-Month Beta 1.44
  • Price/Sales 24.24
  • Price/Cash Flow N/A
  • Price/Book 1.43

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9629 +6.97%
on 09/04/20
1.2340 -16.53%
on 09/18/20
-0.0750 (-6.79%)
since 08/24/20
3-Month
0.9629 +6.97%
on 09/04/20
1.9500 -47.18%
on 07/21/20
-0.1800 (-14.88%)
since 06/24/20
52-Week
0.6200 +66.13%
on 03/16/20
1.9500 -47.18%
on 07/21/20
+0.1594 (+18.31%)
since 09/24/19

Most Recent Stories

More News
Lineage Cell: 2Q Earnings Snapshot

CARLSBAD, Calif. (AP) _ Lineage Cell Therapeutics, Inc. (LCTX) on Thursday reported a loss of $6.5 million in its second quarter.

CTIC : 1.0300 (-1.90%)
CTI BioPharma Reports Second Quarter 2020 Financial Results

, /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter and six months ended .

CTIC : 1.0300 (-1.90%)
CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial

, /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe...

CTIC : 1.0300 (-1.90%)
CTI BioPharma to Present at the Jefferies 2020 Healthcare Conference on Thursday, Jun. 4

, /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies 2020 Healthcare Conference at . The conference will...

CTIC : 1.0300 (-1.90%)
Lineage Cell: 1Q Earnings Snapshot

CARLSBAD, Calif. (AP) _ Lineage Cell Therapeutics, Inc. (LCTX) on Thursday reported a first-quarter loss of $8.4 million, after reporting a profit in the same period a year earlier.

CTIC : 1.0300 (-1.90%)
CTI BioPharma Reports First Quarter 2020 Financial Results

, /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended .

CTIC : 1.0300 (-1.90%)
CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19

CTI BioPharma Corp. (Nasdaq: CTIC) today announced the initiation of PRE-VENT, a Phase 3 study evaluating pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind,...

CTIC : 1.0300 (-1.90%)
Primary Myelofibrosis Pipeline Landscape Analysis, 2020 Featuring Novartis, Geron Corporation, NS Pharma, Actuate Therapeutics, Suzhou Zelgen Biopharmaceuticals, CTI BioPharma, Covance, and More - ResearchAndMarkets.com

The "Primary Myelofibrosis - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

CTIC : 1.0300 (-1.90%)
GERN : 1.6800 (unch)
NVS : 86.30 (-1.32%)
CTI BioPharma to Present at the Needham Healthcare Conference on Wednesday, Apr. 15

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Needham Healthcare Conference at 10:40 a.m. EDT. The conference will be held...

CTIC : 1.0300 (-1.90%)
Lineage Cell: 4Q Earnings Snapshot

CARLSBAD, Calif. (AP) _ Lineage Cell Therapeutics, Inc. (LCTX) on Thursday reported a loss of $4.5 million in its fourth quarter.

CTIC : 1.0300 (-1.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade CTIC with:

Business Summary

CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its...

See More

Key Turning Points

2nd Resistance Point 1.0900
1st Resistance Point 1.0600
Last Price 1.0300
1st Support Level 1.0000
2nd Support Level 0.9700

See More

52-Week High 1.9500
Fibonacci 61.8% 1.4419
Fibonacci 50% 1.2850
Fibonacci 38.2% 1.1281
Last Price 1.0300
52-Week Low 0.6200

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar